Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15355204 | 0.84 | PPARA (0.43) | SLC6A4SLC6A3PPARA | |
| SCHEMBL1912680 | 0.80 | ALDH1A1 (0.49) | SLC6A4SLC6A3ALDH1A1TSHRDAO | |
| SCHEMBL9062148 | 0.80 | TSHR (0.53) | SLC6A4SLC6A3ALDH1A1TSHRDAO | |
| SCHEMBL1687455 | 0.80 | TSHR (0.53) | SLC6A4SLC6A3ALDH1A1TSHRDAO | |
| SCHEMBL26278014 | 0.80 | EPHX2 (0.53) | SLC6A4SLC6A3ALDH1A1TSHRDAO | |
| SCHEMBL7561099 | 0.79 | FFAR1 (0.41) | ALDH1A1PPARALTA4H | |
| SCHEMBL12061947 | 0.79 | CHRM2 (0.56) | DAOPPARAGRIN2B | |
| SCHEMBL9062440 | 0.78 | GRIN2B (0.56) | ALDH1A1TSHRDAOGPR84GRIN2B | |
| SCHEMBL9060027 | 0.78 | TSHR (0.51) | SLC6A4SLC6A3ALDH1A1TSHRDAO | |
| SCHEMBL9061480 | 0.78 | BCHE (0.56) | SLC6A4SLC6A3ALDH1A1TSHRDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2011044375-A2 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2009107799-A1 | PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | 日産化学工業株式会社 (JP) | 2009-09-03 | — | — | WO | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | SLC6A4 2097/4885SLC6A3 1173/4885ALDH1A1 2970/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | SLC6A4 2097/4885SLC6A3 1173/4885ALDH1A1 2970/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | SLC6A4 3275/4885SLC6A3 3350/4885ALDH1A1 3986/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | SLC6A4 2097/4885SLC6A3 1173/4885ALDH1A1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.